COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic |
| |
Authors: | Giulia Costanzo William Cordeddu Luchino Chessa Stefano Del Giacco Davide Firinu |
| |
Institution: | Giulia Costanzo, William Cordeddu, Luchino Chessa, Stefano Del Giacco, Davide Firinu, Department of Medical Sciences and Public Health, University of Cagliari, Monserrato 09042, Cagliari, Italy |
| |
Abstract: | The extent of the profound immunological and nonimmunological responses linked to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is currently being investigated worldwide due to the large burden associated with death due to SARS-CoV-2 and the short-term consequences of coronavirus disease 2019 (COVID-19). It has been hypothesized that patients on immunosuppressive treatments, including biologics, may have an augmented risk of being infected by SARS-CoV-2; however, there are currently no definitive data about biological drugs and COVID-19 in immune-mediated inflammatory diseases. Current epidemiological models developed to understand how long the COVID-19 epidemic may last are not conclusive and range from sustained epidemics to complete elimination. Nevertheless, even in the best-case scenario of apparent elimination, there is concordance about a possible contagion resurgence as late as 2024. Therefore, knowledge of the impact of SARS-CoV-2 on immune-mediated diseases and among patients treated with biologicals, together with the results of novel and promising COVID-19 treatment strategies targeting the virus and the host immune response (or both), will help us to best manage our patients during this pandemic over the next few years. |
| |
Keywords: | COVID-19 Immune-mediated diseases Biological drugs Targeted therapies Cytokine storm Immunosuppressive drugs |
|
| 点击此处可从《》浏览原始摘要信息 |
|